Biosergen AB
STO: BIOSGN.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Tine Kold Olesen
- Employees
- 2
- Headquarters
- Solna, Sweden
- IPO year
- 2021
- Market cap
- SEK 22.7M
- Website
- https://biosergen.net
Loading BIOSGN…
Loading profile data…Frequently asked questions about BIOSGN
What does Biosergen AB (BIOSGN.ST) do?
Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and is headquartered in Solna, Sweden.
Where does BIOSGN.ST trade?
Biosergen AB (BIOSGN.ST) trades on the Stockholm Stock Exchange.
What sector is BIOSGN.ST in?
Biosergen AB (BIOSGN.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Biosergen AB?
Tine Kold Olesen is the chief executive officer of Biosergen AB (BIOSGN.ST).
Where is Biosergen AB headquartered?
Biosergen AB is headquartered in Sweden.
Does BIOSGN.ST pay a dividend?
Biosergen AB (BIOSGN.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BIOSGN.ST go public?
Biosergen AB (BIOSGN.ST) completed its initial public offering in 2021.